453 related articles for article (PubMed ID: 22403278)
41. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency.
Servais A; Noël LH; Dragon-Durey MA; Gübler MC; Rémy P; Buob D; Cordonnier C; Makdassi R; Jaber W; Boulanger E; Lesavre P; Frémeaux-Bacchi V
Hum Pathol; 2011 Sep; 42(9):1305-11. PubMed ID: 21396679
[TBL] [Abstract][Full Text] [Related]
42. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).
Prasto J; Kaplan BS; Russo P; Chan E; Smith RJ; Meyers KE
Eur J Pediatr; 2014 Jun; 173(6):767-72. PubMed ID: 24384791
[TBL] [Abstract][Full Text] [Related]
43. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
44. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
[TBL] [Abstract][Full Text] [Related]
45. Childhood-onset dense deposit disease: a rare cause of proteinuria.
Taranta-Janusz K; Wasilewska A; Szynaka B
Ir J Med Sci; 2014 Sep; 183(3):455-9. PubMed ID: 24338037
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal antibodies for the treatment of the C3 glomerulopathies.
Beck LH
Clin J Am Soc Nephrol; 2012 May; 7(5):704-6. PubMed ID: 22498497
[No Abstract] [Full Text] [Related]
47. Eculizumab in dense-deposit disease after renal transplantation.
Sánchez-Moreno A; De la Cerda F; Cabrera R; Fijo J; López-Trascasa M; Bedoya R; Rodríguez de Córdoba S; Ybot-González P
Pediatr Nephrol; 2014 Oct; 29(10):2055-9. PubMed ID: 24908321
[TBL] [Abstract][Full Text] [Related]
48. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
49. Complement dysregulation in glomerulonephritis.
Kaartinen K; Safa A; Kotha S; Ratti G; Meri S
Semin Immunol; 2019 Oct; 45():101331. PubMed ID: 31711769
[TBL] [Abstract][Full Text] [Related]
50. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
51. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
52. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
53. Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I.
Alfandary H; Davidovits M
Pediatr Nephrol; 2015 Dec; 30(12):2129-34. PubMed ID: 26289290
[TBL] [Abstract][Full Text] [Related]
54. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
55. Retinal disease in the C3 glomerulopathies and the risk of impaired vision.
Savige J; Amos L; Ierino F; Mack HG; Symons RC; Hughes P; Nicholls K; Colville D
Ophthalmic Genet; 2016 Dec; 37(4):369-376. PubMed ID: 26915021
[TBL] [Abstract][Full Text] [Related]
56. A case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency.
Suga K; Kondo S; Matsuura S; Kinoshita Y; Kitano E; Hatanaka M; Kitamura H; Hidaka Y; Oda T; Kagami S
Pediatr Nephrol; 2010 Aug; 25(8):1547-50. PubMed ID: 20221776
[TBL] [Abstract][Full Text] [Related]
57. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
58. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
59. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
[TBL] [Abstract][Full Text] [Related]
60. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
